# In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients

> **NCT05617209** · — · COMPLETED · sponsor: **Centre Hospitalier Universitaire de Saint Etienne** · enrollment: 20 (actual)

## Conditions studied

- Hemophilia

## Interventions

- **OTHER:** thrombin generation measurement

## Key facts

- **NCT ID:** NCT05617209
- **Lead sponsor:** Centre Hospitalier Universitaire de Saint Etienne
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-07
- **Primary completion:** 2023-01-05
- **Final completion:** 2023-01-05
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05617209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05617209, "In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05617209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*